Mina T Kelleni1,2*
1Assistant Professor of Pharmacology, College of Medicine, Minia University, Egypt
2Assistant Professor of Pharmacology, College of Pharmacy, Jouf University, KSA
*Corresponding Author: Mina T Kelleni, Assistant Professor of Pharmacology, College of Medicine, Minia University, Egypt and Assistant Professor of Pharmacology, College of Pharmacy, Jouf University, KSA.
Received: June 27, 2020; Published: July 01, 2020
On the 29th of May, I’ve explained from a pharmacovigilant point of view why remdesivir is least likely to be considered as a safe treatment for COVID-19 patients and I wish to add some other pieces of evidence not mentioned in that rapid response [1].
Citation: Mina T Kelleni. “Remdesivir-Gate for COVID-19”. Acta Scientific Gastrointestinal Disorders 3.8 (2020): 01.
Copyright: © 2020 Mina T Kelleni. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.